Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8152MR)

This product GTTS-WQ8152MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF1A gene. The antibody can be applied in Dry eye (DE) syndrome research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001065.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7132
UniProt ID P19438.1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8152MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10794MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA M777-16-3
GTTS-WQ3640MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ585MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 62-71-3
GTTS-WQ11986MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MM-005
GTTS-WQ8683MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ6404MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CT-011
GTTS-WQ8124MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HH1
GTTS-WQ3202MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARENEGYR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW